Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome — RETINO2018  

Retinoblastoma Clinical Trial

Official title: Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018

Status Recruiting

Clinical Trial Summary

This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients:

• Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.

• Study 2, a minimally invasive interventional study evaluating the results on visual function following reference treatment with intravenous (IV) chemotherapy in association with ophthalmologic or local ophthalmological treatment without IV chemotherapy.

Clinical Trial Description

Primary objective of the studies:

• Study 1: To evaluate the efficacy of IAC in term of local control of the disease in patients eligible for IAC (randomized phase II study);

• Study 2: To assess the visual function, based on World Health Organization (WHO) criteria, in patients eligible for other conservative treatments (IV chemotherapy in association with local ophthalmologic trématent or local ophthalmological treatment without IV chemotherapy; this is a minimally invasive interventional study). ;

Related Conditions & MeSH terms

• Retinoblastoma

• NCT number: NCT04681417
• Study type: Interventional
• Source: Institut Curie
• Contact: Livia LUMBROSO LE ROUIC, MD
• Phone: +33(0)144324163
• Email: livia.lumbroso-lerouic@curie.fr
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: March 25, 2021
• Completion date: January 20, 2036